Bacterin licenses Osteotech IP
This article was originally published in Clinica
Bacterin International, which develops bioactive coating technology for medical devices, transplants and tissue engineering, has licensed patents from Osteotech relating to flowable demineralised bone powder compositions. The non-exclusively licensed rights will be used by Belgrade, Montana-based Bacterin in its transplant development programme. It believes its coating technologies could be beneficially applied to allografts to help reduce bacterial adhesion. The two patents in question underlie Osteotech's Grafton DBM line of tissue grafts.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.